Strategic Advisors LLC Takes Position in Axon Enterprise, Inc. (NASDAQ:AXON)

Strategic Advisors LLC acquired a new stake in Axon Enterprise, Inc. (NASDAQ:AXON) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 427 shares of the biotechnology company’s stock, valued at approximately $254,000.

Several other institutional investors have also modified their holdings of AXON. Geode Capital Management LLC lifted its holdings in shares of Axon Enterprise by 2.0% during the third quarter. Geode Capital Management LLC now owns 1,782,828 shares of the biotechnology company’s stock valued at $710,103,000 after purchasing an additional 35,320 shares during the last quarter. Westfield Capital Management Co. LP lifted its holdings in shares of Axon Enterprise by 12.2% during the third quarter. Westfield Capital Management Co. LP now owns 1,175,328 shares of the biotechnology company’s stock valued at $469,661,000 after purchasing an additional 127,769 shares during the last quarter. Champlain Investment Partners LLC lifted its holdings in shares of Axon Enterprise by 13.9% during the third quarter. Champlain Investment Partners LLC now owns 682,420 shares of the biotechnology company’s stock valued at $272,695,000 after purchasing an additional 83,265 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Axon Enterprise by 1.6% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 561,263 shares of the biotechnology company’s stock valued at $224,281,000 after purchasing an additional 9,090 shares during the last quarter. Finally, Groupama Asset Managment purchased a new stake in shares of Axon Enterprise during the third quarter valued at $200,000. Institutional investors and hedge funds own 79.08% of the company’s stock.

Axon Enterprise Stock Performance

Shares of NASDAQ AXON opened at $683.41 on Tuesday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.63 and a current ratio of 2.96. The firm has a market cap of $52.11 billion, a price-to-earnings ratio of 176.59, a P/E/G ratio of 6.79 and a beta of 1.05. The business’s 50-day simple moving average is $624.03 and its 200-day simple moving average is $511.87. Axon Enterprise, Inc. has a 52 week low of $260.27 and a 52 week high of $698.67.

Insider Activity

In related news, Director Julie A. Cullivan sold 1,261 shares of the stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $682.06, for a total transaction of $860,077.66. Following the completion of the sale, the director now owns 2,392 shares in the company, valued at $1,631,487.52. This represents a 34.52 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Caitlin Elizabeth Kalinowski sold 450 shares of the stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $604.07, for a total value of $271,831.50. Following the sale, the director now owns 6,929 shares of the company’s stock, valued at approximately $4,185,601.03. The trade was a 6.10 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 8,711 shares of company stock valued at $5,631,561. Insiders own 6.10% of the company’s stock.

Wall Street Analyst Weigh In

AXON has been the subject of several analyst reports. The Goldman Sachs Group upped their target price on Axon Enterprise from $500.00 to $700.00 and gave the company a “buy” rating in a report on Monday, January 27th. Morgan Stanley raised Axon Enterprise from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $500.00 to $700.00 in a research note on Tuesday, December 3rd. Needham & Company LLC increased their price objective on Axon Enterprise from $525.00 to $600.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Northland Securities increased their price objective on Axon Enterprise from $365.00 to $550.00 and gave the stock an “outperform” rating in a research note on Monday, November 11th. Finally, Robert W. Baird increased their price objective on Axon Enterprise from $600.00 to $800.00 and gave the stock an “outperform” rating in a research note on Friday, December 6th. One equities research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $542.15.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.